secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0001104659-22-068958
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics interim CSO Glenn Pierce resigns as planned, enters consulting agreement; shareholders re-elect him
--------------------------------------------------------------------------------

- Glenn Pierce resigned as Interim CSO effective June 2, 2022, after serving in the role since June 2021 on a part-time basis.
- On June 6, Pierce signed a consulting agreement with Voyager capped at $120,000, valid until June 5, 2023, for transition services.
- At the June 6 annual meeting, Pierce was re-elected as Class I director with 21,014,996 votes (88.9% of votes cast).
- Shareholders approved say-on-pay with 23,447,480 votes and ratified Ernst & Young as auditor with 30,505,725 votes.
- Todd Carter, SVP Research, assumed increased R&D responsibilities starting June 3, reporting to CEO; search for a CSO is underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/0001104659-22-068958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/tm2217868d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-068958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer